Text Size
1588 studies found for:    Open Studies | "Breast Neoplasms"

Modify this search | How to Use Search Results

Show Display Options
RSS Create an RSS feed from your search for:
Open Studies | "Breast Neoplasms"
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer
Conditions: Tubular Breast Cancer Stage II;   Mucinous Breast Cancer Stage II;   Breast Cancer Female NOS;   Invasive Ductal Breast Cancer;   Tubular Breast Cancer Stage III;   HER-2 Positive Breast Cancer;   Inflammatory Breast Cancer Stage IV;   Inflammatory Breast Cancer
Interventions: Drug: Carboplatin;   Drug: background treatment according to standards fpr triple negative and Her2pos breast cancer patients
2 Recruiting Study Comparing Nanoparticle-based Paclitaxel With Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Patients With Early Breast Cancer (GeparSepto)
Conditions: Tubular Breast Cancer Stage II;   Mucinous Breast Cancer Stage II;   Breast Cancer Female NOS;   Invasive Ductal Breast Cancer;   Tubular Breast Cancer Stage III;   HER-2 Positive Breast Cancer;   Inflammatory Breast Cancer Stage IV;   Inflammatory Breast Cancer
Interventions: Drug: nab-Paclitaxel;   Drug: Paclitaxel
3 Recruiting Vaccine Therapy in Combination With Rintatolimod and/or Sargramostim in Patients With Stage II-IV HER2-Positive Breast Cancer
Conditions: HER2-positive Breast Cancer;   Male Breast Cancer;   Recurrent Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
Interventions: Biological: HER-2/neu peptide vaccine;   Biological: sargramostim;   Drug: rintatolimod;   Other: laboratory biomarker analysis
4 Recruiting Veliparib, Cisplatin, and Vinorelbine Ditartrate in Treating Patients With Recurrent and/or Metastatic Breast Cancer
Conditions: Estrogen Receptor-negative Breast Cancer;   Hereditary Breast/Ovarian Cancer - BRCA1;   Hereditary Breast/Ovarian Cancer - BRCA2;   Male Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer;   Triple-negative Breast Cancer
Interventions: Other: immunohistochemistry staining method;   Genetic: gene expression analysis;   Drug: veliparib;   Drug: cisplatin;   Drug: vinorelbine tartrate;   Other: pharmacological study;   Other: laboratory biomarker analysis
5 Recruiting Neoadjuvant Trial of Eribulin Followed by Dose Dense Doxorubicin and Cyclophosphamide for Her2-negative, Locally Advanced Breast Cancer
Conditions: Breast Neoplasms;   Breast Cancer;   Breast Tumors;   Cancer of the Breast;   Neoplasms, Breast;   Tumors, Breast
Interventions: Drug: Eribulin;   Drug: Doxorubicin;   Drug: Cyclophosphamide
6 Recruiting Hormone Therapy Or Chemotherapy Before Surgery Based on Gene Expression Analysis in Treating Patients With Breast Cancer
Conditions: Ductal Breast Carcinoma in Situ;   Lobular Breast Carcinoma in Situ;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer
Interventions: Procedure: neoadjuvant therapy;   Procedure: therapeutic conventional surgery;   Other: laboratory biomarker analysis;   Other: enzyme-linked immunosorbent assay;   Genetic: gene expression analysis;   Drug: systemic chemotherapy;   Drug: tamoxifen citrate;   Drug: aromatase inhibition therapy
7 Recruiting Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer
Conditions: Estrogen Receptor-positive Breast Cancer;   HER2-negative Breast Cancer;   Progesterone Receptor-positive Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
Interventions: Drug: systemic chemotherapy;   Drug: tamoxifen citrate;   Drug: anastrozole;   Drug: exemestane;   Drug: letrozole
8 Recruiting Laboratory Treated T Cells After Chemotherapy in Treating Patients With HER2-Negative Stage II-III Breast Cancer That Can Be Removed By Surgery
Conditions: Ductal Breast Carcinoma in Situ;   Lobular Breast Carcinoma in Situ;   Male Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer
Interventions: Drug: Doxorubicin;   Drug: Cyclophosphamide;   Drug: Paclitaxel;   Drug: Docetaxel;   Biological: HER2Bi-armed activated T cells;   Other: laboratory biomarker analysis;   Procedure: therapeutic conventional surgery
9 Recruiting Azacitidine and Entinostat in Treating Patients With Advanced Breast Cancer
Conditions: Estrogen Receptor-negative Breast Cancer;   Estrogen Receptor-positive Breast Cancer;   HER2-negative Breast Cancer;   Male Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Recurrent Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer;   Triple-negative Breast Cancer
Interventions: Drug: entinostat;   Other: diagnostic laboratory biomarker analysis;   Other: pharmacological study;   Drug: azacitidine
10 Recruiting MUC1 Vaccine for Triple-negative Breast Cancer
Conditions: Breast Cancer;   Inflammatory Breast Cancer;   Stage I Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Triple-negative Breast Cancer
Interventions: Biological: MUC-1 peptide vaccine;   Biological: poly ICLC;   Biological: MUC1 peptide-poly-ICLC adjuvant vaccine;   Other: laboratory biomarker analysis;   Other: enzyme-linked immunosorbent assay;   Other: flow cytometry
11 Recruiting Veliparib and Carboplatin in Treating Women With HER2-Negative Metastatic Breast Cancer
Conditions: BRCA1 Mutation Carrier;   BRCA2 Mutation Carrier;   Estrogen Receptor-negative Breast Cancer;   Estrogen Receptor-positive Breast Cancer;   HER2-negative Breast Cancer;   Male Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Progesterone Receptor-positive Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer;   Triple-negative Breast Cancer
Interventions: Drug: veliparib;   Other: fluorine F 18 fluorothymidine;   Other: diagnostic laboratory biomarker analysis;   Other: pharmacological study;   Drug: carboplatin
12 Recruiting Accelerated Radiation Therapy After Surgery in Treating Patients With Breast Cancer
Conditions: Inflammatory Breast Cancer;   Invasive Ductal Breast Carcinoma;   Invasive Lobular Breast Carcinoma;   Mucinous Ductal Breast Carcinoma;   Papillary Ductal Breast Carcinoma;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Tubular Ductal Breast Carcinoma
Intervention: Radiation: External beam radiation therapy
13 Recruiting BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer
Conditions: Estrogen Receptor-positive Breast Cancer;   HER2-negative Breast Cancer;   Invasive Ductal Breast Carcinoma;   Progesterone Receptor-positive Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: PI3K inhibitor BYL719;   Drug: letrozole;   Other: laboratory biomarker analysis;   Other: pharmacological studies
14 Recruiting Cyclophosphamide With or Without Veliparib in Patients With Locally Advanced or Metastatic Breast Cancer
Conditions: Estrogen Receptor-positive Breast Cancer;   HER2-negative Breast Cancer;   Male Breast Cancer;   Progesterone Receptor-positive Breast Cancer;   Recurrent Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: veliparib;   Drug: cyclophosphamide;   Other: placebo;   Other: laboratory biomarker analysis
15 Recruiting Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097, Paclitaxel, And Carboplatin Before Surgery in Treating Patients With Stage II or Stage III Triple-Negative Breast Cancer
Conditions: Estrogen Receptor-negative Breast Cancer;   HER2-negative Breast Cancer;   Male Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Triple-negative Breast Cancer
Interventions: Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097;   Drug: carboplatin;   Drug: paclitaxel;   Procedure: therapeutic conventional surgery;   Other: pharmacological study;   Other: laboratory biomarker analysis
16 Recruiting Dinaciclib and Epirubicin Hydrochloride in Treating Patients With Metastatic Triple-Negative Breast Cancer
Conditions: Estrogen Receptor-negative Breast Cancer;   HER2-negative Breast Cancer;   Male Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer;   Triple-negative Breast Cancer
Interventions: Drug: dinaciclib;   Drug: epirubicin hydrochloride;   Other: laboratory biomarker analysis
17 Recruiting Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer
Conditions: Breast Cancer;   Breast Neoplasms;   Breast Tumors;   Cancer;   Locally Recurrent and Metastatic Breast Cancer;   Metastases;   Metastatic Cancer;   Oncology;   Solid Tumors;   Tumors
Interventions: Drug: AMG 386 15 mg/kg, Capecitabine and Lapatinib;   Drug: AMG 386 15mg/kg, Paclitaxel and Trastuzumab;   Drug: AMG 386 30 mg/kg, Paclitaxel and Trastuzumab;   Drug: AMG 386 30 mg/kg, Capecitabine and Lapatinib;   Drug: AMG 386 10 mgkg, Paclitaxel and Trastuzumab;   Drug: AMG 386 10 mg/kg, Capecitabine and Lapatinib
18 Recruiting Nab-paclitaxel (Abraxane) With or Without Mifepristone in Patients With Advanced Breast Cancer
Conditions: Male Breast Cancer;   Recurrent Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: mifepristone;   Drug: placebo;   Drug: nab-paclitaxel
19 Recruiting Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Locally Advanced or Inflammatory Triple Negative Breast Cancer
Conditions: Inflammatory Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Triple-negative Breast Cancer
Interventions: Drug: carboplatin;   Drug: paclitaxel albumin-stabilized nanoparticle formulation;   Other: laboratory biomarker analysis
20 Recruiting Akt Inhibitor MK2206 in Combination With Lapatinib Ditosylate in Patients With Advanced or Metastatic Solid Tumors or Breast Cancer
Conditions: HER2-positive Breast Cancer;   Male Breast Cancer;   Recurrent Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: Akt inhibitor MK2206;   Drug: lapatinib ditosylate;   Other: pharmacological study;   Other: laboratory biomarker analysis
To Top

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
† Indicates status has not been verified in more than two years